ZNF582 hypermethylation as a highly specific biomarker for triage of high-grade cervical lesions in HR-HPV positive women
Authors:
Open Access
- 11 December 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1687869
Abstract
Objective: Persistent infection with high-risk human papillomavirus (HR-HPV) is the primary cause of cervical cancer (CC). DNA methylation is a promising biomarker for cervical cancer screening. This study aimed to validate the clinical efficacy of a cytological DNA methylation-based ZNF 582 methylation ( ZNF582 m ) test for triage in detecting cervical intraepithelial neoplasia (CIN) grade 3 or higher (CIN3+) among women with HR-HPV infection. Methods: This case–control study examined 199 women who tested positive for HR-HPV from the colposcopy clinic. The cohort included 15 cases of CC, 37 cases of CIN3, 45 cases of CIN2, 49 cases of CIN1, and 53 normal cases. Using cervical pathology results as a reference, the performance of the ZNF582 m test for detecting CIN3 + was evaluated and compared with liquid-based cytology (LBC) and P16/Ki67 double stain cytology (DSC). Results: ZNF582 m test showed statistically significant differences in pathological results between CIN2 and CIN3 ( p < 0.001). The area under the receiver operating characteristic curve (AUC) for distinguishing between ZNF582 m test was 0.797 ( p < 0.001). The ZNF582 m test demonstrated higher specificity (88.4, 95% CI, 82.1–93.1%) compared to cytology (≥ atypical squamous cells of undetermined significance; ≥ASC-US+: 28.6, 95% CI: 21.4–36.6%) and P16/Ki67 DSC (43.5, 95% CI, 35.4–52.0%) for detecting CIN3+, establishing it as a superior triage biomarker for women with HR-HPV infection. The Kappa value between the ZNF582 m test and pathology ( ZNF582 m test was found to be the highest among other combined tests, at 63.3% (95% CI = 54.9–71.1%). Conclusion: The ZNF582 m test exhibiting superior triage performance compared to P16/Ki67 DSC and LBC (ASC-US+). The ZNF582 m test enhances specificity ( p < 0.001), thereby facilitating the accurate identification of CIN3 + lesions while reducing unnecessary colposcopies. This is particularly crucial in resource-limited settings, where optimizing the accuracy of triage for HR-HPV positive women is essential.Keywords
This publication has 48 references indexed in Scilit:
- Colposcopy referrals and CIN3 detection after triage by host cell DNA methylation and/or HPV genotyping in HPV positive women with low‐grade cytology from a population‐based Dutch primary HPV screening trialInternational Journal of Cancer, 2024
- Cervical Cancer ScreeningJAMA, 2023
- p16/Ki67 dual stain triage versus cytology in primary human papillomavirus‐based cervical cancer screening with limited genotypingJournal of Medical Virology, 2023
- Validation of novel DNA methylation markers in cervical precancer and cancerInternational Journal of Cancer, 2023
- Oncogenic role of an uncharacterized cold‐induced zinc finger protein 726 in breast cancerJournal of Cellular Biochemistry, 2023
- DNA methylation testing with S5 for triage of high‐risk HPV positive womenInternational Journal of Cancer, 2022
- Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in ChinaJAMA Oncology, 2021
- Methylation markers FAM19A4 and miR124‐2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter studyInternational Journal of Cancer, 2020
- Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening ProgramJAMA Internal Medicine, 2019
- Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive WomenJAMA Oncology, 2019